Actuate CEO gets 272,055 shares from RSU vest

Actuate Therapeutics, Inc. President and CEO Daniel M. Schmitt reported the vesting and settlement of 272,055 restricted stock units on February 13, 2026, converting into the same number of common shares at $0 per share.

Rhea-AI Filing Summary

Actuate Therapeutics, Inc. President and CEO Daniel M. Schmitt reported the vesting and settlement of 272,055 restricted stock units on February 13, 2026, converting into the same number of common shares at $0 per share. To cover federal and state withholding taxes, the issuer withheld 121,874 shares of common stock valued at $4.33 per share, leaving Schmitt with 150,181 directly held common shares and 272,056 RSUs outstanding. He also reports indirect ownership of additional common shares through several irrevocable family trusts for which he serves as trustee.

Insider Trade Summary

272,055 shares exercised/converted

Exercise 7 txns

Insider SCHMITT DANIEL M

Role President, CEO and Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	272,055	$0.00	$0.00
Exercise	Common Stock	272,055	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	121,874	$4.33	$528K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 272,056 contracts (Direct); Common Stock — 150,181 shares (Direct); Common Stock — 564,071 shares (Indirect, By The Schmitt Family Irrevocable Trust, dated December 31, 2019); Common Stock — 22,223 shares (Indirect, By The Andrew Schmitt Irrevocable Trust, dated December 31, 2019); Common Stock — 22,223 shares (Indirect, By The Anna Schmitt Irrevocable Trust, dated December 31, 2019); Common Stock — 22,223 shares (Indirect, By The Edward Schmitt Irrevocable Trust, dated December 31, 2019)

Footnotes (9)

1. F1. Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs").
2. F2. Represents the closing price of Issuer's common stock on February 13, 2026.
3. F3. Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1).
4. F4. Each restricted stock unit represents a contingent right to receive one share of common stock.
5. F5. 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026.
6. F6. Represents shares held by The Schmitt Family Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee (the "Schmitt Family Trust").
7. F7. Represents shares held by The Andrew Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.
8. F8. Represents shares held by The Anna Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.
9. F9. Represents shares held by The Edward Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ACTU CEO Daniel Schmitt report on February 13, 2026?

Daniel Schmitt reported the vesting and settlement of 272,055 restricted stock units, converting into 272,055 shares of common stock at $0 per share. The transaction reflects equity compensation becoming actual shares, not an open-market purchase.

How many Actuate Therapeutics (ACTU) shares were withheld for taxes in this Form 4?

The issuer withheld 121,874 shares of common stock to satisfy federal and state withholding taxes related to the RSU settlement. These shares were valued using the $4.33 closing price on February 13, 2026, and represent a tax-withholding disposition, not a market sale.

How many Actuate Therapeutics (ACTU) shares does Daniel Schmitt own directly after this filing?

After the reported transactions, Daniel Schmitt directly holds 150,181 shares of common stock. In addition, he holds 272,056 restricted stock units that may convert into common shares upon future vesting, reflecting ongoing equity-based compensation from the company.

What is the origin of the 544,111 RSUs granted to ACTU CEO Daniel Schmitt?

Schmitt received 544,111 restricted stock units at the closing of Actuate Therapeutics’ initial public offering on August 14, 2024. Of these, 272,055 vested on August 14, 2025 and settled on February 13, 2026, while 272,056 vest on August 14, 2026.

What indirect Actuate Therapeutics (ACTU) shareholdings does Daniel Schmitt report?

Schmitt reports indirect ownership of common stock through several irrevocable trusts dated December 31, 2019. These include 564,071 shares held by The Schmitt Family Irrevocable Trust and 22,223 shares each held by the Andrew, Anna, and Edward Schmitt Irrevocable Trusts.

Does the ACTU Form 4 indicate an open-market purchase or sale by Daniel Schmitt?

The Form 4 shows a derivative conversion of RSUs into common shares and a tax-withholding disposition of shares at $4.33 per share. It does not report an open-market purchase or sale; activity is tied to equity award vesting and tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHMITT DANIEL M

(Last) (First) (Middle)

C/O ACTUATE THERAPEUTICS, INC.

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH TX 76107

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Director

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		272,055(3)	A	$0(4)	272,055(3)	D
Common Stock	02/13/2026		F		121,874(1)	D	$4.33(2)	150,181(1)	D
Common Stock								564,071	I	By The Schmitt Family Irrevocable Trust, dated December 31, 2019(6)
Common Stock								22,223	I	By The Andrew Schmitt Irrevocable Trust, dated December 31, 2019(7)
Common Stock								22,223	I	By The Anna Schmitt Irrevocable Trust, dated December 31, 2019(8)
Common Stock								22,223	I	By The Edward Schmitt Irrevocable Trust, dated December 31, 2019(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	02/13/2026		M			272,055	(5)	(5)	Common Stock	272,055	$0(4)	272,056	D

Explanation of Responses:

1. Represents 121,874 shares of common stock withheld by Issuer to satisfy federal and state withholding taxes owed by holder upon the settlement of restricted stock units ("RSUs").

2. Represents the closing price of Issuer's common stock on February 13, 2026.

3. Represents the issuance of 272,055 shares of common stock from the vesting and settlement of 272,055 RSUs, which number excludes the withholding of 121,874 shares by Issuer to satisfy federal and state withholding taxes due at settlement (see Note 1).

4. Each restricted stock unit represents a contingent right to receive one share of common stock.

5. 544,111 restricted stock units were granted upon the closing of the issuer's initial public offering on August 14, 2024, of which, 272,055 vested on August 14, 2025 (and settled on February 13, 2026) and 272,056 vest on August 14, 2026.

6. Represents shares held by The Schmitt Family Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee (the "Schmitt Family Trust").

7. Represents shares held by The Andrew Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.

8. Represents shares held by The Anna Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.

9. Represents shares held by The Edward Schmitt Irrevocable Trust, dated December 31, 2019, of which the reporting person is trustee.

	/s/ Paul Lytle, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.